Release date: 2016-08-03
On July 29, VytronUS, a privately held medical device company, completed a $49 million Series C equity financing.
This round of investment comes from investment groups, including Apple Tree Partners, NEA, BioStar Ventures, and Windham Venture Partners, and the proceeds will be used for technical improvements and clinical trials of VytronUS' proprietary Low-Intensity Collimated Ultrasound (LICU) cardiac mapping and ablation systems. To treat atrial fibrillation and other arrhythmias.
It is understood that VytronUS is developing a next-generation integrated imaging and ablation platform for cardiac electrophysiologists. Utilizing the power of ultrasound energy, the VytronUS system creates a high-resolution image of the heart's interior for program planning and allows the doctor to simply draw a desired treatment pattern on the image on the workstation.
“VytronUS offers a potential combination of atrial fibrillation (AF) and VT ablation: simple mapping of the left atrial left atrium or ventricular anatomy, continuous transmural lesions without tissue contact, and more importantly, by manipulation The flexibility of the lesion path defined by the tissue thickness information," said Vivek Reddy, MD, of Mount Sinai Hospital.
“This financing is the culmination of the company’s remarkable progress over the past two years. From our successful clinical results to date, we have developed a potential technology platform for 'changing the rules of the game',†said VytronUS CEO John Pavlidis. . “We are very grateful to our esteemed investor group for their commitment to fund the implementation of our technology in multi-center EU and US clinical validation.â€
Apple Tree Partners partner and VytronUS managing partner David McIntyre also commented, "Despite the obvious limitations of currently available technologies, catheter ablation is still one of the fastest growing segments of the medical device industry, and we will continue Passionate about investing in VytronUS's technology platform and excellent team."
"We have become a long-time supporter of VytronUS because we believe the company's revolutionary technology is likely to help millions of people around the world," added Justin Klein, a partner at NEA, a managing partner at VytronUS, and a doctorate in medicine and a doctorate in law. With this latest investment, the company is more likely to succeed in multi-center clinical trials."
In addition, VytronUS official website shows that it was founded in 2006 and announced on October 29, 2014 that it completed a $31.6 million Series B round of financing, including Apple Tree Partners, BioStar Ventures, and Windham Venture Partners.
Source: 36æ°ª
JIANGSU CLS TECHNOLOGY CORP.LTD , https://www.js-cls.com